AbbVie succeeds in mid-stage study of neurological disease treatment

[Neuron system disease]

AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) announced that its mid-stage study of Botox (onabotulinumtoxinA) for treating essential tremor in the upper limbs achieved its main goal.

The research successfully reached its primary goal, showing significant improvements in the tremor disability scale for onabotulinumtoxinA compared to placebo at the 18-week mark.

In particular, participants receiving onabotulinumtoxinA experienced a more substantial decrease in their total unilateral scores on the scale compared to those on the placebo.

AbbVie said [https://seekingalpha.com/pr/20255528-abbvie-announces-positive-topline-results-from-phase-2-elate-trial-evaluating]that the study additionally achieved all six of its secondary goals.

When it came to safety, the company added that results were consistent with the established safety profile of onabotulinumtoxinA.

MORE ON ABBVIE

* AbbVie: Wins Accumulating While We Wait For Next BD Steps [https://seekingalpha.com/article/4827703-abbvie-wins-accumulating-while-we-wait-for-next-bd-steps]
* AbbVie For Healthy Dividend Growth [https://seekingalpha.com/article/4826365-abbvie-for-healthy-dividend-growth]
* AbbVie: Best Time To Sell In 5 Years (Rating Downgrade) [https://seekingalpha.com/article/4823412-abbvie-best-time-to-sell-in-5-years-rating-downgrade]
* Notable analyst calls this week: J&J, PayPal and Corteva among top picks [https://seekingalpha.com/news/4501759-notable-analyst-calls-this-week-jj-paypal-and-corteva-among-top-picks]
* AbbVie sees negative Q3, full-year impact from IPR&D and milestones expense [https://seekingalpha.com/news/4501795-abbvie-sees-negative-q3-full-year-impact-ipr-and-d-milestones-expense]